TY - JOUR
T1 - Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
T2 - Clinical practice guidelines in oncology
AU - Spiess, Philippe E.
AU - Agarwal, Neeraj
AU - Bangs, Rick
AU - Boorjian, Stephen A.
AU - Buyyounouski, Mark K.
AU - Clark, Peter E.
AU - Downs, Tracy M.
AU - Efstathiou, Jason A.
AU - Flaig, Thomas W.
AU - Friedlander, Terence
AU - Greenberg, Richard E.
AU - Guru, Khurshid A.
AU - Hahn, Noah
AU - Herr, Harry W.
AU - Hoimes, Christopher
AU - Inman, Brant A.
AU - Jimbo, Masahito
AU - Kader, A. Karim
AU - Lele, Subodh M.
AU - Meeks, Joshua J.
AU - Michalski, Jeff
AU - Montgomery, Jeffrey S.
AU - Pagliaro, Lance C.
AU - Pal, Sumanta K.
AU - Patterson, Anthony
AU - Plimack, Elizabeth R.
AU - Pohar, Kamal S.
AU - Porter, Michael P.
AU - Preston, Mark A.
AU - Sexton, Wade J.
AU - Siefker-Radtke, Arlene O.
AU - Sonpavde, Guru
AU - Tward, Jonathan
AU - Wile, Geoffrey
AU - Dwyer, Mary A.
AU - Gurski, Lisa A.
N1 - Publisher Copyright:
© JNCCN - Journal of the National Comprehensive Cancer Network.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, at-ezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
AB - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, at-ezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
KW - Combined Modality Therapy/methods
KW - Humans
KW - Neoplasm Invasiveness
KW - Neoplasm Metastasis
KW - Neoplasm Staging
KW - Treatment Outcome
KW - Urinary Bladder Neoplasms/diagnosis
UR - https://www.scopus.com/pages/publications/85030858287
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000412320900010&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2017.0156
DO - 10.6004/jnccn.2017.0156
M3 - Review article
C2 - 28982750
SN - 1540-1405
VL - 15
SP - 1240
EP - 1267
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 10
ER -
SDG 3 Good Health and Well-being